Phillygenin Protects the Intestinal Barrier from Dysfunction via let-7b Signaling Pathway and Regulation of...

Area of Science:

• Gastroenterology
• Molecular Biology
• Microbiome Research

Background:

• Intestinal barrier dysfunction is implicated in various gastrointestinal diseases.
• The let-7b microRNA and intestinal microbiota play critical roles in maintaining gut health.
• Phillygenin is a compound with potential therapeutic properties.

Purpose of the Study:

• To investigate the protective effects of phillygenin on intestinal tight junctions.
• To elucidate the role of the let-7b signaling pathway and intestinal microbiota in phillygenin's action.
• To explore phillygenin as a therapeutic agent for intestinal barrier dysfunction.

Main Methods:

• Quantitative PCR and Western blotting to assess tight junction protein expression.
• Dextran Sodium Sulfate (DSS)-induced colitis mouse model to evaluate intestinal barrier integrity.
• Fecal microbiota transplantation (FMT) to determine the role of gut microbiota.
• Analysis of colon tissues from patients with acute stercoral obstruction.

Main Results:

• Phillygenin increased the expression of occludin, a key tight junction protein.
• Phillygenin reduced colonic permeability and preserved tight junction proteins in a DSS-induced colitis model.
• The protective effects of phillygenin were dependent on let-7b signaling and gut microbiota composition.
• Lower levels of let-7b were observed in colon tissues of patients with acute stercoral obstruction.

Conclusions:

• Phillygenin protects the intestinal barrier from dysfunction by modulating the let-7b signaling pathway and regulating intestinal microbiota.
• Phillygenin demonstrates therapeutic potential for conditions characterized by intestinal barrier impairment.
• Targeting the let-7b pathway and gut microbiota represents a promising strategy for enhancing intestinal barrier function.